Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00103649 · ClinicalTrials.gov registry record · Phase 3
18-Month Study of the Efficacy of Xaliproden (SR57746A) in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type
A Phase 3 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,306
- Enrollment target
NCT00103649: Completed Phase 3 study, sponsored by Sanofi.
NCT00103649 is a Phase 3 study that has completed, run by Sanofi. The registered enrollment target is 1,306 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (69% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00103649, a Phase 3 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,306 participants
- Enrollment target
Study Summary
The purpose of this study is to assess xaliproden's potential capacity of slowing the deterioration of cognitive and global functions in patients with mild to moderate Alzheimer's disease. The patients participating in this study will take orally once daily xaliproden or placebo (inactive substance pill).
Interventions
- DRUG xaliproden (SR57746A)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,306 participants |
| Start Date | 2003-11 |
| Est. Completion | 2007-10 |
| Phase | Phase 3 |
What the finished NCT00103649 record still lists
NCT00103649 is an interventional study that assigns participants to a tested intervention. Its 1,306 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (69% higher).
The record links to 0 conditions, and to 1 intervention - of which xaliproden (SR57746A) is the first listed.
NCT00103649 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00103649 about?
NCT00103649 is a clinical study titled "18-Month Study of the Efficacy of Xaliproden (SR57746A) in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type". The purpose of this study is to assess xaliproden's potential capacity of slowing the deterioration of cognitive and global functions in patients with mild to moderate Alzheimer's disease. The patients participating in this study will take orally once daily xaliproden or placebo (inactive substance ...
What is the current status of trial NCT00103649?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,306 participants. The study started on 2003-11. Estimated completion is 2007-10.
What interventions are being tested in trial NCT00103649?
The interventions under investigation include: xaliproden (SR57746A) (DRUG).
Who is sponsoring clinical trial NCT00103649?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00103649's enrollment target sits among peer trials
1,306 188th of 2000 higher than 1,813 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06517901 · 1,306 participants · NA
Fusion or Cognitive Ultrasound-guided Biopsy to Detect Prostate Cancer
- NCT04171323 · 1,305 participants · NA
The Active Mind Trial: An Adaptive Randomized Trial to Improve Function and Delay Dementia
- NCT06136624 · 1,310 participants · Phase 3
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
- NCT06556433 · 1,312 participants · NA
Family-Based Financial Incentives Intervention for Smoking Cessation
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia